| BA166475 |
1668553-26-1 |
A 1210477 |
|
Inhibits anti-apoptotic protein MCL1; antineoplastic |
BIO-X |
| BA166576 |
2089148-71-8 |
A 395 |
|
Inhibitor of polycomb protein EED |
BIO-X |
| BA166577 |
1445993-26-9 |
ABBV 075 |
|
Inhibitor of BET bromodomain; antineoplastic |
BIO-X |
| BA166477 |
2138861-99-9 |
ABBV 744 |
|
BET bromodomain inhibitor selective for BDII |
BIO-X |
| FA16902 |
852808-04-9 |
ABT 737 |
|
Inhibitor of Bcl-2, Bcl-xl and Bcl-w pro-survival proteins |
BIO-X |
| FI139131 |
331731-18-1 |
Adalimumab |
Antibody |
Monoclonal antibody against TNFα; therapy for rheumatoid arthritis |
|
| BA165580 |
862111-32-8 |
Aflibercept |
|
Recombinant protein against VEGF(A); binds placental growth factor (PIGF) |
|
| BA165581 |
216503-57-0 |
Alemtuzumab |
Antibody |
Monoclonal antibody against CD52; treatment for multiple sclerosis; anti-cancer |
|
| AA17307 |
75747-14-7 |
17-Allylaminogeldanamycin |
|
Hsp90 inhibitor; anti-neoplastic antibiotic |
BIO-X |
| FC158737 |
1352066-68-2 |
AMG 232 |
|
Inhibits MDM2-p53 interaction |
BIO-X |
| BA17365 |
64202-81-9 |
17-Aminogeldanamycin |
|
Inhibits chaperone protein Hsp90; antineoplastic |
BIO-X |
| BA166663 |
916151-99-0 |
APTO 253 |
|
Induces Kruppel like factor 4 (KLF4), inhibits MYC expression; anti-cancer agent |
BIO-X |
| FA159625 |
289893-27-2 |
(2S)-Arimoclomol |
|
Regulates expression of chaperonins Hsp70 and Hsp90 |
|
| FA30834 |
289893-25-0 |
(2R-)Arimoclomol NEW |
|
Regulates expression of chaperonins Hsp70 and Hsp90 |
BIO-X |
| FA159626 |
289893-28-3 |
(2S)-Arimoclomol maleate |
|
|
|
| FA159627 |
289893-26-1 |
(2R)-Arimoclomol maleate |
|
|
BIO-X |
| BA166845 |
1799328-86-1 |
ASTX 660 |
|
Antagonist of the inhibitor-of-apoptosis-proteins cIAP1/2 and XIAP |
BIO-X |
| BA165584 |
1380723-44-3 |
Atezolizumab |
Antibody |
Monoclonal antibody against PDL-1; anti-cancer agent |
|
| BA171490 |
|
Autogramin 2 |
|
Autophagy inhibitor that selectively targets the StART domain of GRAMD1A |
BIO-X |
| BA165583 |
1537032-82-8 |
Avelumab |
Antibody |
Monoclonal antibody against PDL-1; targeted immunotherapy for cancer |
|
| FA137649 |
1124329-14-1 |
AZ 3146 |
|
Monopolar spindle 1 (MPS-1) antagonist |
BIO-X |
| FB15804 |
218600-53-4 |
Bardoxolone methyl |
|
Activates nuclear factor erythroid 2–related factor 2 (Nrf2) |
|
| BB163665 |
2080306-23-4 |
BAY 299 |
|
Inhibitor of BRPF2 and TAF1 bromodomains |
BIO-X |
| BB171473 |
|
BI 9321 |
|
Nuclear receptor binding SET domain (NSD) 3 antagonist; selectively binds PWWP1 |
BIO-X |
| FB139172 |
130493-03-7 |
Bimoclomol |
|
Heat shock protein (HSP) co-inducer |
|
| BB161276 |
130641-38-2 |
Bindarit |
|
Inhibitor of MCP-1 chemokine synthesis; indazolic derivative |
|
| FB18841 |
294891-81-9 |
BML 286 |
|
Inhibits dishevelled (Dvl)-PDZ domain interaction; affects Wnt signaling pathway |
|
| BB164045 |
|
Brentuximab |
Antibody |
Antibody-drug conjugate targeting CD30; antineoplastic |
|
| BB161996 |
357336-20-0 |
Brivaracetam |
|
Binds to synaptic vesicle protein SV2A; analog of levetiracetam; anti-epileptic |
BIO-X |
| BB170570 |
1619994-69-2 |
Bromosporine |
|
Broad spectrum bromodomain inhibitor |
BIO-X |
| BB168381 |
924537-98-4 |
BT 13 NEW |
|
Inhibitor of RET signalling; GFL mimetic |
BIO-X |
| BB170419 |
924811-53-0 |
BT 18 |
|
Agonist of receptor tyrosine kinase RetA |
BIO-X |
| BC165662 |
1197996-80-7 |
CBL 0137 |
|
Activator of p53; inhibitor of NF-κB |
BIO-X |
| BC167790 |
1177921-72-0 |
CBR 470-1 |
|
Activates NRF2 signalling |
BIO-X |
| FC76600 |
1443437-74-8 |
CCG 203971 |
|
Inhibits MRTF-SRF transcriptional pathway |
BIO-X |
| FC64971 |
620112-78-9 |
CCG 63802 |
|
Inhibits RGS proteins, selective for RGS4 |
BIO-X |
| FC64972 |
620113-73-7 |
CCG 63808 |
|
Reversible inhibitor of RGS proteins |
BIO-X |
| BC168608 |
1693731-40-6 |
CCT 251236 |
|
|
BIO-X |
| FC64978 |
205923-56-4 |
Cetuximab - Buffer solution |
Antibody |
Monoclonal antibody against EGFR; treatment for colorectal cancer |
|
| BC166449 |
|
CM 11 |
|
Modulator of VHL E3 ubiquitin ligase dimerization |
|
| FC20540 |
209810-38-8 |
(R/S)-Colchicine |
|
Disrupts tubulin polymerization; destabilizes microtubules; treatment for gout |
|
| FC20545 |
117048-59-6 |
Combretastatin A4 |
|
Tubulin binding agent; targets tumour vasculature |
|
| FC20718 |
4449-51-8 |
Cyclopamine |
|
Inhibitor of Smoothened receptor and Hedgehog signalling |
BIO-X |
| FC20757 |
83602-39-5 |
Cyclosporin H |
|
Formyl peptide receptor-1 (FPR-1) antagonist |
|
| FC11288 |
14930-96-2 |
Cytochalasin B |
|
Blocker of the actin monomers to the actin filament |
BIO-X |
| FC29349 |
22144-77-0 |
Cytochalasin D |
|
Inhibits actin polymerization |
BIO-X |
| BD165586 |
945721-28-8 |
Daratumumab - 20mg/ml in water |
Antibody |
Monoclonal antibody against CD38; treatment for multiple myeloma |
|
| BD165585 |
615258-40-7 |
Denosumab |
Antibody |
Monoclonal antibody against RANKL; anti-resorptive agent for osteoperosis treatment |
|
| BD164046 |
1363687-32-4 |
Dinutuximab |
Antibody |
Anti-GD2 monoclonal antibody |
|
| AD34908 |
467214-21-7 |
17-DMAG hydrochloride |
|
Heat shock protein 90 (HSP90) inhibitor |
BIO-X |